Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

ClinicalTrials.gov ID: NCT02520284

Public ClinicalTrials.gov record NCT02520284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis

Study identification

NCT ID
NCT02520284
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
165 participants

Conditions and interventions

Interventions

  • Andecaliximab Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2015
Primary completion
Aug 31, 2016
Completion
Oct 31, 2016
Last update posted
Apr 9, 2019

2015 – 2016

United States locations

U.S. sites
33
U.S. states
19
U.S. cities
33
Facility City State ZIP Site status
Not listed Dothan Alabama
Not listed Wheat Ridge Colorado
Not listed Lauderdale Lakes Florida
Not listed Miramar Florida
Not listed Winter Park Florida
Not listed Zephyrhills Florida
Not listed Chicago Illinois
Not listed Topeka Kansas
Not listed Louisville Kentucky
Not listed Monroe Louisiana
Not listed Ann Arbor Michigan
Not listed Plymouth Minnesota
Not listed St Louis Missouri
Not listed Egg Harbor New Jersey
Not listed New York New York
Not listed Chapel Hill North Carolina
Not listed Charlotte North Carolina
Not listed Mentor Ohio
Not listed Rochester Ohio
Not listed Germantown Tennessee
Not listed Hermitage Tennessee
Not listed Arlington Texas
Not listed Baytown Texas
Not listed Houston Texas
Not listed Irving Texas
Not listed San Antonio Texas
Not listed Southlake Texas
Not listed Charlottesville Virginia
Not listed Chesapeake Virginia
Not listed Norfolk Virginia
Not listed Richmond Virginia
Not listed Seattle Washington
Not listed Wauwatosa Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02520284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 9, 2019 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02520284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →